Appia Bio
David Moskowitz, PhD, focuses on the Bio-IT space as a principal at 8VC. Prior to joining 8VC, David completed his PhD in biomedical informatics at Stanford University, where he concurrently received an MS in statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells. Previously, David was a bioinformatic analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).